First paediatric EC approval of HIV drug
The European Commission has granted the first paediatric marketing authorisation for Gilead's low-dose Biktarvy® HIV tablet.
List view / Grid view
The European Commission has granted the first paediatric marketing authorisation for Gilead's low-dose Biktarvy® HIV tablet.
Gilead's Biktarvy demonstrated a consistently high efficacy of over 95 percent in analyses of the ongoing real-world cohort BICSTaR study.
Drug makers have hiked the price of over 250 drugs in the US so far in 2020, according to new reports.
The FDA has approved Biktarvy a once-daily single-tablet regimen for the treatment of HIV-1 infection...